• Je něco špatně v tomto záznamu ?

Duration of Follow-up and Timing of Discharge from Imaging Follow-up, in Adult Patients with Urolithiasis After Surgical or Medical Intervention: A Systematic Review and Meta-analysis from the European Association of Urology Guideline Panel on Urolithiasis

L. Tzelves, R. Geraghty, R. Lombardo, NF. Davis, A. Petřík, A. Neisius, G. Gambaro, C. Türk, K. Thomas, B. Somani, A. Skolarikos

. 2023 ; 9 (1) : 188-198. [pub] 20220716

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, metaanalýza, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004833

CONTEXT: No algorithm exists for structured follow-up of urolithiasis patients. OBJECTIVE: To provide a discharge time point during follow-up of urolithiasis patients after treatment. EVIDENCE ACQUISITION: We performed a systematic review of PubMed/Medline, EMBASE, Cochrane Library, clinicaltrials.gov, and reference lists according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Fifty studies were eligible. EVIDENCE SYNTHESIS: From a pooled analysis of 5467 stone-free patients, we estimated that for a safety margin of 80% for remaining stone free, patients should be followed up using imaging, for at least 2 yr (radiopaque stones) or 3 yr (radiolucent stones) before being discharged. Patients should be discharged after 5 yr of no recurrence with a safety margin of 90%. Regarding residual disease, patients with fragments ≤4 mm could be offered surveillance up to 4 yr since intervention rates range between 17% and 29%, disease progression between 9% and 34%, and spontaneous passage between 21% and 34% at 49 mo. Patients with larger residual fragments should be offered further definitive intervention since intervention rates are high (24-100%). Insufficient data exist for high-risk patients, but the current literature dictates that patients who are adherent to targeted medical treatment seem to experience less stone growth or regrowth of residual fragments, and may be discharged after 36-48 mo of nonprogressive disease on imaging. CONCLUSIONS: This systematic review and meta-analysis indicates that stone-free patients with radiopaque or radiolucent stones should be followed up to 2 or 3 yr, respectively. In patients with residual fragments ≤4 mm, surveillance or intervention can be advised according to patient preferences and characteristics, while for those with larger residual fragments, reintervention should be scheduled. PATIENT SUMMARY: Here, we review the literature regarding follow-up of urolithiasis patients. Patients who have no stones after treatment should be seen up to 2-3 yr, those with large fragments should be reoperated, and those with small fragments could be offered surveillance with imaging.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004833
003      
CZ-PrNML
005      
20230425171739.0
007      
ta
008      
230418s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euf.2022.06.016 $2 doi
035    __
$a (PubMed)35851252
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Tzelves, Lazaros $u Department of Urology, Sismanogleio Hospital, National and Kapodistrian University of Athens, Athens, Greece
245    10
$a Duration of Follow-up and Timing of Discharge from Imaging Follow-up, in Adult Patients with Urolithiasis After Surgical or Medical Intervention: A Systematic Review and Meta-analysis from the European Association of Urology Guideline Panel on Urolithiasis / $c L. Tzelves, R. Geraghty, R. Lombardo, NF. Davis, A. Petřík, A. Neisius, G. Gambaro, C. Türk, K. Thomas, B. Somani, A. Skolarikos
520    9_
$a CONTEXT: No algorithm exists for structured follow-up of urolithiasis patients. OBJECTIVE: To provide a discharge time point during follow-up of urolithiasis patients after treatment. EVIDENCE ACQUISITION: We performed a systematic review of PubMed/Medline, EMBASE, Cochrane Library, clinicaltrials.gov, and reference lists according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Fifty studies were eligible. EVIDENCE SYNTHESIS: From a pooled analysis of 5467 stone-free patients, we estimated that for a safety margin of 80% for remaining stone free, patients should be followed up using imaging, for at least 2 yr (radiopaque stones) or 3 yr (radiolucent stones) before being discharged. Patients should be discharged after 5 yr of no recurrence with a safety margin of 90%. Regarding residual disease, patients with fragments ≤4 mm could be offered surveillance up to 4 yr since intervention rates range between 17% and 29%, disease progression between 9% and 34%, and spontaneous passage between 21% and 34% at 49 mo. Patients with larger residual fragments should be offered further definitive intervention since intervention rates are high (24-100%). Insufficient data exist for high-risk patients, but the current literature dictates that patients who are adherent to targeted medical treatment seem to experience less stone growth or regrowth of residual fragments, and may be discharged after 36-48 mo of nonprogressive disease on imaging. CONCLUSIONS: This systematic review and meta-analysis indicates that stone-free patients with radiopaque or radiolucent stones should be followed up to 2 or 3 yr, respectively. In patients with residual fragments ≤4 mm, surveillance or intervention can be advised according to patient preferences and characteristics, while for those with larger residual fragments, reintervention should be scheduled. PATIENT SUMMARY: Here, we review the literature regarding follow-up of urolithiasis patients. Patients who have no stones after treatment should be seen up to 2-3 yr, those with large fragments should be reoperated, and those with small fragments could be offered surveillance with imaging.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a následné studie $7 D005500
650    12
$a litotripse $x škodlivé účinky $7 D008096
650    _2
$a propuštění pacienta $7 D010351
650    12
$a urolitiáza $x diagnostické zobrazování $x chirurgie $7 D052878
650    12
$a urologie $7 D014572
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Geraghty, Robert $u Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, UK; Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, UK
700    1_
$a Lombardo, Riccardo $u Sant 'Andrea Hospital, Sapienza University, Rome, Italy
700    1_
$a Davis, Niall F $u Department of Urology, Connolly Hospital, Blanchardstown, Dublin, Ireland
700    1_
$a Petřík, Ales $u Department of Urology, Region Hospital, Ceske Budejovice, Czech Republic; Department of Urology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Neisius, Andreas $u Department of Urology, Hospital of the Brothers of Mercy Trier, Medical Campus University Mainz, Trier, Germany
700    1_
$a Gambaro, Giovanni $u Division of Nephrology and Dialysis, Department of Medicine, University of Verona, Verona, Italy
700    1_
$a Türk, Christian $u Department of Urology, Hospital of the Sisters of Charity, Vienna, Austria; Urologische Praxis, Vienna, Austria
700    1_
$a Thomas, Kay $u Department of Urology, Guy's and St Thomas' Hospital, London, UK
700    1_
$a Somani, Bhaskar $u Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
700    1_
$a Skolarikos, Andreas $u Department of Urology, Sismanogleio Hospital, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: andskol@yahoo.com
773    0_
$w MED00193513 $t European urology focus $x 2405-4569 $g Roč. 9, č. 1 (2023), s. 188-198
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35851252 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171735 $b ABA008
999    __
$a ok $b bmc $g 1925117 $s 1191042
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 9 $c 1 $d 188-198 $e 20220716 $i 2405-4569 $m European urology focus $n Eur Urol Focus $x MED00193513
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace